Business
Cost and time savings in manufacture of biologics
Cost and time savings in manufacture of biologics.
About this update from Metir Plc
[{"type":"text","content":"\n \nRNS Number : 8431A Microsaic Systems plc 03 June 2019 \n\n3 June 2019\nMicrosaic Systems plc\n \n(\"Microsaic\" or the \"Company\")\n \nMicrosaic's technology breakthrough demonstrates cost and time savings in the manufacture of biologics \n \nMicrosaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry (\"MS\") instruments, has developed proof of concept workflows to analyse in real-time complex samples from bioreactors, which could enable customers to achieve significant costs and time savings.\n \nAn independent laboratory was engaged to compare the use of Microsaic's MiD® ProteinID technology as an in-situ technique for measuring small and large molecules during the manufacture of biologics compared with the use of traditionally accepted bioanalysers. The results were obtained by quantifying small-molecule cell media as well as measuring intact proteins. Microsaic's MS technology detected metabolites not usually seen by traditional methods during the bio-manufacturing process.\nThe results will be presented at the American Association of Mass Spectrometry Week on 3 June 2019, in Atlanta, US. A copy of the results is available on the Microsaic website at www.microsaic.com/resources/application-notes/. \nFrom the information obtained, Microsaic estimates that there are potentially substantial savings available for its customers by switching from traditional analysis methods to Microsaic's MiD® ProteinID technology.\nOn 5 March 2019, Microsaic published early results with the Massachusetts Institute of Technology (MIT) which demonstrated the real-time analysis of complex protein feedstocks: the results highlighted the importance of storage conditions between fresh fed batch and frozen perfusion samples to beneficial biologic manufacture outcomes.\nGlenn Tracey, CEO of Microsaic, commented: \"These latest results are extremely exciting for the Company and mark yet another important milestone in the strategy set out when I took on the role of CEO. \nWhat we have demonstrated is the potential for our technology to replace very expensive analysers, which have been the mainstay of bio-analysis over time. As our technology can measure small and large molecules simultaneously, we can potentially replace workflows which use several analysis techniques costing hundreds of thousands o...